Search results for "Star"

showing 10 items of 4285 documents

Effect of thickener on disintegration, dissolution and permeability of common drug products for elderly patients

2019

Dysphagia is a very common problem suffered by elderly patients. The use of thickeners during administration in these patients helps to prevent difficulties with swallowing larger solid dosage forms. However, there are several indications when the thickeners may influence disintegration and dissolution processes of solid dosage forms, potentially affecting therapeutic efficacy. In this paper the effects of a commonly used thickener on tablet disintegration, dissolution and subsequent absorption of 6 formulated drugs frequently used in elderly patients (Aspirin, Atenolol, Acenocumarol, Candesartan, Ramipril and Valsartan) in two different administration conditions (intact tablet and crushed …

DrugDrug Compoundingmedia_common.quotation_subjectPharmaceutical Science02 engineering and technologyPharmacology030226 pharmacology & pharmacyPermeabilityDosage form03 medical and health sciences0302 clinical medicinemedicineAnimalsHumansIn patientDissolution testingRats WistarDissolutionAgedmedia_commonViscosityChemistryGeneral Medicine021001 nanoscience & nanotechnologyAtenololRatsDrug LiberationSolubilityPermeability (electromagnetism)Deglutition Disorders0210 nano-technologyTabletsBiotechnologymedicine.drugEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen.

2018

The oral controlled release (CR) formulations have become more important in recent years. Among them, the polymeric nanoparticles have been thoroughly studied during the last decades, consequently they are extensively employed for a broad range of applications and drugs. The objective of this research was to develop polymeric nanoparticles (NPs) of ibuprofen with poly(lactic-co-glycolic) acid (PLGA) as polymer, and to test their applicability for oral CR formulations development. Different proportions of drug/polymer were employed to develop the ibuprofen NPs and their in vitro release profiles were analysed. The in situ segmental permeability of ibuprofen was tested in Wistar rat and demon…

DrugMaleColonPolymersmedia_common.quotation_subjectPharmaceutical ScienceIbuprofen02 engineering and technologyAbsorption (skin)030226 pharmacology & pharmacyPermeability03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug Delivery SystemsPolylactic Acid-Polyglycolic Acid CopolymerIn vivomedicineAnimalsLactic AcidRats Wistarmedia_commonchemistry.chemical_classificationDrug CarriersChromatographyorganic chemicalstechnology industry and agriculturePolymer021001 nanoscience & nanotechnologyIbuprofenControlled releaseRatsPLGAchemistryIntestinal AbsorptionPermeability (electromagnetism)Delayed-Action PreparationsNanoparticles0210 nano-technologyPolyglycolic Acidmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Development of an ion-pair to improve the colon permeability of a low permeability drug: Atenolol.

2016

Abstract To ensure the optimal performance of oral controlled release formulations, drug colon permeability is one of the critical parameters. Consequently developing this kind of formulations for low permeability molecules requires strategies to increase their ability to cross the colonic membrane. The objective of this work is to show if an ion-pair formation can improve the colon permeability of atenolol as a low permeability drug model. Two counter ions have been tested: brilliant blue and bromophenol blue. The Distribution coefficients at pH 7.00 (DpH7) of atenolol, atenolol + brilliant blue and atenolol + bromophenol blue were experimentally determined in n-octanol. Moreover, the colo…

DrugMaleColonmedia_common.quotation_subjectPharmaceutical ScienceBromophenol blue02 engineering and technology030226 pharmacology & pharmacyPermeability03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineLow permeabilityAnimalsRats WistarColoring Agentsmedia_commonchemistry.chemical_classificationChromatographyBenzenesulfonates021001 nanoscience & nanotechnologyAtenololPermeability (earth sciences)MembranechemistryAtenololParacellular transportDelayed-Action PreparationsBromphenol BlueCounterion0210 nano-technologymedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Comparing metoclopramide electrotransport kinetics in vitro and in vivo.

2010

The purpose of this work was to investigate the transdermal iontophoretic delivery of metoclopramide and to determine (i) the dependence of electrotransport on current density and drug concentration, (ii) the relative contributions of electromigration and electroosmosis and (iii) the feasibility of administering therapeutic amounts of drug, using a drug-sparing iontophoretic configuration. Iontophoretic delivery of metoclopramide (MCL) across dermatomed porcine ear skin was investigated in vitro as a function of concentration (10, 20, 40, 80 and 100mM) and current density (0.1, 0.2 and 0.3mAcm(-2)) using vertical flow-through diffusion cells. In vivo studies were performed in Wistar rats (4…

DrugMaleMetoclopramideMetoclopramideSwinemedia_common.quotation_subjectPharmaceutical SciencePharmacologyPharmaceutical formulationIn Vitro TechniquesPharmacokineticsIn vivomedicineAnimalsRats WistarAntiemetics/pharmacokineticsMetoclopramide/pharmacokineticsmedia_commonTransdermalddc:615IontophoresisChemistryIn vitroRatsAntiemeticsmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.

2007

An increasing number of newly developed drugs show bioavailability problems due to poor water solubility. Formulating the drugs as nanosuspensions may help to overcome these problems by increasing saturation solubility and dissolution velocity. In the present study the bioavailability of the poorly soluble fenofibrate following oral administration was investigated in rats. Four formulations were tested: a nanosuspension type DissoCube(R), one solid lipid nanoparticle (SLN) preparation and two suspensions of micronized fenofibrate as reference formulations, one suspension in sirupus simplex and a second in a solution of hydroxyethy-cellulose in physiological saline. Both colloidal drug deliv…

DrugMalemedia_common.quotation_subjectPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyModels BiologicalDosage formPharmacokineticsFenofibrateSuspensionsSolid lipid nanoparticlemedicineAnimalsComputer SimulationTissue DistributionSolubilityRats Wistarmedia_commonHypolipidemic AgentsFenofibrateChemistryLipidsBioavailabilityRatsSolubilityDrug deliveryNanoparticlesmedicine.drugAdvanced drug delivery reviews
researchProduct

Hypolipidaemic effects of fenofibrate are not altered by mildronate-mediated normalization of carnitine concentration in rat liver.

1999

The five-fold higher carnitine content in the liver of fenofibrate-treated rats addresses the question about the possible role of this enhancement in the hypolipidaemic effect of the drug and the underlying mechanisms. When fenofibrate was administered with mildronate (a gamma-butyrobetaine hydroxylase inhibitor) in suitable amount, the content in carnitine was found to be normalized in liver. However, triglyceride contents of liver and serum were then at least as low as in rats treated by fenofibrate only. When carnitine concentration was lowered by mildronate to the third of the normal value, a marked increase in triglycerides occurred both in liver and serum, while the five-fold increase…

DrugMalemedicine.medical_specialtymedia_common.quotation_subjectBlood lipidsKetone BodiesBiochemistrychemistry.chemical_compoundFenofibrateInternal medicineCarnitinemedicineAnimalsCarnitineRats WistarMuscle SkeletalBeta oxidationPhospholipidsTriglyceridesmedia_commonHypolipidemic AgentsFenofibrateTriglycerideChemistryMyocardiumGeneral MedicinePeroxisomeRatsEndocrinologyCholesterolBiochemistryLiverKetone bodiesmedicine.drugMethylhydrazinesBiochimie
researchProduct

Ion-pair approach coupled with nanoparticle formation to increase bioavailability of a low permeability charged drug.

2018

Abstract Atenolol is a drug widely used for the treatment of hypertension. However, the great drawback it presents is a low bioavailability after oral administration. To obtain formulations that allow to improve the bioavailability of this drug is a challenge for the pharmaceutical technology. The objective of this work was to increase the rate and extent of intestinal absorption of atenolol as model of a low permeability drug, developing a double technology strategy. To increase atenolol permeability an ion pair with brilliant blue was designed and the sustained release achieved through encapsulation in polymeric nanoparticles (NPs). The in vitro release studies showed a pH-dependent relea…

Drugmedia_common.quotation_subjectPharmaceutical ScienceAdministration OralBiological Availability02 engineering and technology030226 pharmacology & pharmacyIntestinal absorptionPermeability03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug Delivery SystemsPolylactic Acid-Polyglycolic Acid CopolymerIn vivoOral administrationmedicineAnimalsRats WistarAntihypertensive Agentsmedia_commonChromatographyChemistryBenzenesulfonates021001 nanoscience & nanotechnologyAtenololControlled releaseBioavailabilityPLGADrug LiberationAtenololIntestinal AbsorptionNanoparticles0210 nano-technologymedicine.drugInternational journal of pharmaceutics
researchProduct

Observational Approach and Perspective

1983

Well you did not cover more than half of my planned talk! (laughter). Let me comment on interferometric techniques, in particular speckle imaging which you mentioned. Doing speckle imaging with the largest telescopes now available will not give you better than the theoretical resolving power of the telescope. With a 4m telescope that is about 30 marc sec in the visible. That happens to be the radius of the supergiant Betelguese. So you are not going to achieve much with speckle imaging on these stars. One technique which has not been adequately exploited is that of lunar occultation which can give much better angular resolution than speckle, of the order of 2-3 marc sec. By using suitably c…

Dwarf starComputer scienceAstrophysics::Instrumentation and Methods for AstrophysicsAstronomyOccultationlaw.inventionTelescopeSpeckle patternInterferometryStarslawAstrophysics::Solar and Stellar AstrophysicsAngular resolutionAstrophysics::Earth and Planetary AstrophysicsSpeckle imagingAstrophysics::Galaxy Astrophysics
researchProduct

Appeal against the Decision on the Application for a Declaration on enforceability. Procedure to Contest the Decision Given on Appeal. Refusal or Rev…

2016

Lo scritto è un commento agli articoli da 50 a 58 del Regolamento n. 650 del 2012 del Parlamento Europeo e del Consiglio del 4 luglio 2012, relativo alla competenza, alla legge applicabile, al riconoscimento e all’esecuzione delle decisioni e all’accettazione e all’esecuzione degli atti pubblici in materia di successioni e alla creazione di un certificato successorio europeo. Lo scritto affronta i temi relativi alla impugnazione avverso la decisione emessa in seguito alla istanza per il riconoscimento delle sentenze e dei provvedimenti stranieri nelle materie oggetto del regolamento; il procedimento per impugnare le sentenza emesse in seguito all'appello; il rifiuto o la revoca del riconosc…

EU Regulation No 650/2012 on jurisdiction applicable law recognition and enforcement of decisions and acceptance and enforcement of authentic instruments in matters of succession - Decision given in a Member State - Enforceability - Procedure to Contest the Decision on EnforceabilitySettore IUS/15 - Diritto Processuale CivileRegolamento n. 650 del 2012 del Parlamento Europeo e del Consiglio del 4 luglio 2012 relativo alla competenza alla legge applicabile al riconoscimento e all’esecuzione delle decisioni in materia di successioni - Decisioni rese in altri Stati membri - Esecutività - Procedimenti per contestare la decisione emessa sulla istanza per il riconoscimento delle sentenze e dei provvedimenti stranieri
researchProduct

Unveiling the strong interaction among hadrons at the LHC

2020

One of the key challenges for nuclear physics today is to understand from first principles the effective interaction between hadrons with different quark content. First successes have been achieved using techniques that solve the dynamics of quarks and gluons on discrete space-time lattices1,2. Experimentally, the dynamics of the strong interaction have been studied by scattering hadrons off each other. Such scattering experiments are difficult or impossible for unstable hadrons3–6 and so high-quality measurements exist only for hadrons containing up and down quarks7. Here we demonstrate that measuring correlations in the momentum space between hadron pairs8–12 produced in ultrarelativistic…

EXCHANGE-POTENTIAL APPROACHStrange quarkALICE CollaborationHadronNuclear TheoryStrong interaction; hadron collisionsPosition and momentum spacehiukkasfysiikkanucl-ex7. Clean energy01 natural sciencesVDP::Fysikk: 430High Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)Hadron-Hadron scattering (experiments)scattering [hadron]p p scattering[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]scattering [p p]Nuclear Experiment (nucl-ex)Experimental nuclear physicsNUCLEONNuclear ExperimentNuclear ExperimentVDP::Physics: 430PhysicsMultidisciplinaryLarge Hadron ColliderPhysicsstrong interactionlattice [space-time]Publisher CorrectionPRIRODNE ZNANOSTI. Fizika.EXCHANGE-POTENTIAL APPROACH; BARYON-BARYON SCATTERING; NUCLEONCERN LHC CollLHCddc:500NucleonBARYON-BARYON SCATTERINGParticle Physics - Experimentdiscrete [space-time]QuarkParticle physicshadron collisionsCERN LabGeneral Science & TechnologyStrong interactionFOS: Physical sciencesshort-rangeHadron strong interaction LHC114 Physical sciences:Fysikk: 430 [VDP]Articlehadron scatteringquarkultrarelativistic proton–proton collisions LHC ALICE0103 physical sciencesNuclear Physics - ExperimentGeneral010306 general physics:Physics: 430 [VDP]interaction [hadron hadron]hep-ex010308 nuclear & particles physicsHigh Energy Physics::Phenomenologyeffect [strong interaction]hadron-hadron interactionhadron scattering ; hadron-hadron interaction ; strong interaction: effect ; space-time: discrete ; space-time: lattice ; p p scattering ; quark ; correlation ; CERN LHC CollNATURAL SCIENCES. Physics.BaryoncorrelationHypernuclei; Neutron Stars; StrangenessPhysics::Accelerator PhysicsHigh Energy Physics::ExperimenthadronExperimental particle physicsNature
researchProduct